StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Truist Securities Reiterates Buy Rating on Regeneron Pharma (REGN) After Eylea Deemed Inapplicable for MFN Rule
January 4, 2021 7:46 AM
Truist Securities analyst Robyn Karnauskas reiterated a Buy rating and $770.00 price target on Regeneron Pharma (NASDAQ: REGN) after the ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments